ZA200603181B - 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety - Google Patents

3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety Download PDF

Info

Publication number
ZA200603181B
ZA200603181B ZA200603181A ZA200603181A ZA200603181B ZA 200603181 B ZA200603181 B ZA 200603181B ZA 200603181 A ZA200603181 A ZA 200603181A ZA 200603181 A ZA200603181 A ZA 200603181A ZA 200603181 B ZA200603181 B ZA 200603181B
Authority
ZA
South Africa
Prior art keywords
formula
compound
group
ring
alkoxy
Prior art date
Application number
ZA200603181A
Other languages
English (en)
Inventor
Kevin K Barvian
Donald L Hertzog
Anthony L Handlon
Clifton E Hyman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200603181B publication Critical patent/ZA200603181B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200603181A 2003-10-23 2006-04-20 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety ZA200603181B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51380003P 2003-10-23 2003-10-23

Publications (1)

Publication Number Publication Date
ZA200603181B true ZA200603181B (en) 2008-01-30

Family

ID=34549304

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200603181A ZA200603181B (en) 2003-10-23 2006-04-20 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety

Country Status (15)

Country Link
US (1) US20070078125A1 (2)
EP (1) EP1678184A1 (2)
JP (1) JP2007509158A (2)
KR (1) KR20060100412A (2)
CN (1) CN1871242A (2)
AU (1) AU2004285913A1 (2)
BR (1) BRPI0415667A (2)
CA (1) CA2543122A1 (2)
CO (1) CO5690599A2 (2)
IL (1) IL174693A0 (2)
MA (1) MA28111A1 (2)
MX (1) MXPA06003997A (2)
NO (1) NO20061909L (2)
WO (1) WO2005042541A1 (2)
ZA (1) ZA200603181B (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501217A (ja) * 2005-07-15 2009-01-15 アストラゼネカ アクチボラグ 治療薬
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8329704B2 (en) 2005-12-21 2012-12-11 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use in MCH-1 mediated diseases
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP1987020B1 (en) * 2006-02-15 2012-10-03 Sanofi Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2007093365A2 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
EP1986646A1 (en) 2006-02-15 2008-11-05 Sanofi-Aventis Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
KR20080094699A (ko) * 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
MX2008015662A (es) * 2006-06-08 2009-01-12 Lilly Co Eli Nuevos receptores antagonistas de la hormona concentradora de melanina (mch).
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
EP2121654A1 (en) 2007-01-10 2009-11-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
JP2010525077A (ja) 2007-04-25 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 非塩基性メラニン凝集ホルモン受容体−1アンタゴニスト
KR20100044225A (ko) 2007-07-21 2010-04-29 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010104818A1 (en) * 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
KR20130013199A (ko) * 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
EP2747693B1 (en) 2011-08-26 2018-05-09 ON Light Sciences, Inc. Tattoo removal system and method
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124627D0 (en) * 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
JP2007509158A (ja) 2007-04-12
US20070078125A1 (en) 2007-04-05
MXPA06003997A (es) 2006-07-05
BRPI0415667A (pt) 2006-12-19
CO5690599A2 (es) 2006-10-31
WO2005042541A1 (en) 2005-05-12
KR20060100412A (ko) 2006-09-20
EP1678184A1 (en) 2006-07-12
CA2543122A1 (en) 2005-05-12
MA28111A1 (fr) 2006-08-01
NO20061909L (no) 2006-05-03
IL174693A0 (en) 2006-08-20
CN1871242A (zh) 2006-11-29
AU2004285913A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
ZA200603181B (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
AU2009331179B2 (en) Novel bicyclic heterocyclic compound
US11203597B2 (en) Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
EA019309B1 (ru) Модуляторы ampk (амф-активируемой протеинкиназы)
KR20120101980A (ko) 스피로-옥스인돌 화합물의 거울상이성질체 및 치료제로서의 그의 용도
TW201004939A (en) Novel compounds
JP2001302546A (ja) Ii型糖尿病を発症する危険性の高い個体を予防的に処置する方法
JP2010518026A (ja) ナトリウムチャネルが介在する疾患または状態の治療に有用なピリドピリミジノン化合物
KR101216296B1 (ko) 티에노피리디논 화합물 및 치료 방법
WO2014165090A1 (en) Compounds for the treatment of tuberculosis
US20240368113A1 (en) Amide compound and use thereof
JP4740116B2 (ja) 精神疾患および神経障害の処置のための5−ht受容体アンタゴニスト
WO2003057161A2 (en) BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF
EA015745B1 (ru) Соединения, проявляющие активность в отношении св
CA2700113A1 (en) Indazole acrylic acid amide compound
WO2003057213A2 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
DK2546255T3 (en) benzazepine
JP2006500315A (ja) 糖尿病状態に用いるヒスタミン−3受容体リガンド
JPWO2017022733A1 (ja) ピペラジン誘導体
RU2204558C2 (ru) Производное бензоксазола, лекарственное средство на его основе и способ лечения состояния синдрома раздраженного кишечника или функционального расстройства пищеварительного тракта
US9085539B2 (en) Cyclic N,N′-diarylthiourea—androgen receptor antagonist, anti breast cancer composition and use thereof
JP2019507773A (ja) インドールアミン2,3−ジオキシゲナーゼの阻害剤
CA2557758A1 (en) Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
TW201617333A (zh) 吲哚化合物
CN120569387A (zh) Par2的小分子调节剂及其用途